Learning Disability
What is Learning Disability (LD)?
LD is a neurological disorder. In simple terms, LD results from a difference in the way a person's brain is "wired". LDs can affect neurocognitive processes and may manifest as an imperfect ability to listen, speak, read, spell, write, reason, concentrate, solve mathematical problems, or organize information. LDs may have problems with self-regulating behavior, social perception, and social interaction, but these problems do not in themselves constitute LD. LD can't be cured or fixed, this is a lifelong problem.
Common Types of LDs
- Dyslexia
- Dyscalculia
- Dysgraphia
- Auditory and Visual Processing Disorders
- Nonverbal Learning Disabilities
A language barrier is that a person cannot understand written words. It may also be called a reading disability.

A mathematical handicap is that a person has difficulty in solving arithmetic problems and mastering mathematical concepts.
A writing disability is which a person has difficulty in writing letters in each space.
Sensory impairment is that a person has difficulty in understanding language even with normal hearing and vision.
A neurological disorder that originates in the right hemisphere of the brain and causes problems with visual-spatial, intuitive, organizational, evaluative, and overall processing functions.
Current Status of Research in LD
- Cognitive Correlates
- Genetic Factors
- Neural Factors
Cognitive skills are systematically and differentially correlated with academic skills in the six domains of LDs. Consistent with early work on phonological awareness, word-level LDs are marked by a conspicuous problem with the ability to phonologically represent written words. Problems with spatial perception and executive functions have long been implicated in neuropsychological research on children with specific computational disabilities. In written expression, transcription problems are related to difficulties with fine motor skills, finger recognition and proprioception, and perceptual-motor skills. Spelling is related to phonological awareness and is usually impaired in those with word-level reading disabilities.
The advent of contemporary genetics methods has enormously influenced the scientific understanding of LDs. This research takes three forms: (1) familial patterns, (2) twin studies, and (3) molecular genetics.
In a meta-analysis, 41-74% of the variance in reading achievement and up to 90% of the variance in reading-related processes could be attributed to genetic factors. From the research, numerous candidate loci (i.e., regions of the genome potentially harboring dyslexia-related genes) and a dozen candidate genes have been identified for structural variations that may be associated with variations in reading and reading-related traits. Genetic influences differ and vary with age for math calculation, problem-solving, and fluency.
Significant understanding of the role of the brain in LDs has emerged because of the advent of noninvasive structural and functional neuroimaging. The functional neuroimaging research converges in identifying a network of three left hemisphere regions that support proficient reading and are impaired in people with word-level disorders. The future of neuroimaging research lies with the capacity for multi-modal methods that co-register structural and functional modalities, linking with genetic studies associated with brain development, and eventually metabolic studies through spectroscopy.
Fig.1 Framework representing different sources of variability that influence academic outcomes in children with learning disabilities. (Fletcher, 2017)
Creative Biolabs is a leading international company in the field of neuroscience. We can apply our extensive experience with a learning disability to develop the necessary analysis for your project. You can count on our skilled and passionate workforce to find the most suitable path and to guide you through your clinical journey. Please feel free to contact us.
Reference
- Fletcher, J.M.; Grigorenko, E.L. Neuropsychology of Learning Disabilities: The Past and the Future. J Int Neuropsychol Soc. 2017 Oct; 23(9-10): 930-940.
- NeuroMab™ Anti-TREM2 BBB Shuttle Antibody(NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- NeuroMab™ Anti-Alpha Synuclein Antibody(NRP-0422-P614) (Cat#: NRP-0422-P614)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P517) (Cat#: NRP-0422-P517)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- NeuroMab™ Anti-CD20 Antibody(NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- pAAV-syn-FLEX-jGCaMP8f-WPRE (Cat#: NTA-2106-P064)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)